VP, Product - Oncology – Liquid Biopsy

Location: New York

Recent advancements in underlying technology have finally made it possible for AI to impact clinical care in a meaningful way. Tempus' proprietary platform connects an entire ecosystem of real-world evidence to deliver real-time, actionable insights to physicians, providing critical information about the right treatments for the right patients, at the right time.
** Responsibilities:
*** Liquid Biopsy Portfolio

Roadmap:

Define and execute a high-growth roadmap for liquid biopsy products, prioritizing applications such as therapy selection and treatment monitoring.
* Commercial Strategy & Market Creation:
Lead the "Go-to-Market" engine. Develop high-impact positioning, pricing strategies, and evidence-generation plans to drive physician adoption and overcome the barriers to blood-based testing.
* Phase-Gated Product Development (PDP):
Implement and oversee a disciplined PDP, ensuring all liquid biopsy assays move efficiently from feasibility to clinical validation and commercialization.
* Market & Competitive Intelligence:
Maintain a "battle-ready" understanding of the liquid biopsy landscape (e.g., Guardant Health, Natera, Grail) to differentiate our platform through superior sensitivity, turnaround time, or clinical utility.
* P&L & Business Growth:
Full accountability for the liquid biopsy business unit’s P&L. Monitor revenue, margins, and market share, making data-driven pivots to resource allocation to maximize ROI.
* Reimbursement & Market Access:
Partner with Market Access teams to secure favorable coverage (LCDs/NCDs). Ensure the product value proposition aligns with the requirements of private payers and Medicare.
* KOL & Clinical Engagement:
Act as the face of the product line with top-tier oncologists and clinical investigators to catalyze the adoption of liquid biopsy in standard-of-care guidelines.
*
* Required Skills:

*** Strategic Commercial Leadership:
Ability to transform technical assay specs into a "Value Story" that resonates with payers, health systems, and community oncologists.
* Product Development Process (PDP) Mastery:
Proven ability to lead multidisciplinary teams through formal phase-gate processes, ensuring products are "Built to Scale" and "Built to Sell."
* Clinical & Scientific Fluency:
Ability to engage as a peer with R&D and Medical Affairs to define clinically meaningful performance specifications (e.g., Limit of Detection, Sensitivity/Specificity).
* Data-Driven Decision Making:
Proficiency in using market analytics, CRM data, and diagnostic volume trends to forecast demand and optimize the commercial funnel.
* Health Economics and Outcomes Research (HEOR):
Understanding of how to leverage clinical trial data to build economic models that justify the cost-offset of liquid biopsy over traditional tissue biopsy.
** Required

Education & Experience:

*** Required

Education:

Bachelor’s degree in Molecular Biology, Genetics, or a related Life Science field.

* Preferred Education:

MBA combined with a PhD or MD is highly preferred to bridge the gap between complex genomic science and commercial execution.
* Specialized Knowledge:
Expert-level understanding of circulating tumor DNA (ctDNA), cell-free DNA (cfDNA) biology, NGS technologies, and the clinical utility of liquid biopsy across the cancer continuum
* Commercial Knowledge:
Extensive knowledge of market demands, technology trends, and the regulatory environment for oncology molecular diagnostics.
*
* Preferred Experience:

*** Leadership Tenure:
Minimum of 10+ years in the molecular diagnostics or biotech industry, with at least 5 years in a senior leadership role focused on Liquid Biopsy.
* Launch Success: A documented track record of successfully launching at least two major oncology diagnostic products, preferably liquid-based assays, with measurable market share gains.
* Commercial Oversight:
Experience managing a significant P&L ($50M+) and leading cross-functional teams in a matrixed environment.
* Ecosystem Navigation:
Demonstrated success in navigating the complex interplay between diagnostic providers, biopharma partners, and third-party payers.

This role works with Personal Health Information (PHI) on a regular basis both in paper…